The aim of this study was to investigate the influence of histology and site of analysis (primary tumor versus lymph node) on the expression of genes involved in gemcitabine and cisplatin activity in non-small-cell lung cancer (NSCLC). Excision repair cross-complementing-1 (ERCC1), human equilibrative nucleoside transporter-1 (hENT1), deoxycytidine kinase (dCK), 5 0 -nucleotidase (5 0 -NT), cytidine deaminase (CDA) and ribonucleotidereductase regulatory subunits (RRM1 and RRM2) were analyzed by quantitative-reverse transcription-PCR in 88 microdissected samples from 69 chemonaive patients. The results showed different patterns of expression for all studied genes, suggesting a possible stratification of the patients. No difference was observed between primary tumor and lymph node metastasis, as well as in adenocarcinoma and squamous-cell carcinoma specimens, while we found a correlation between the CDA-A79C polymorphism and gene expression levels. These data suggest a similar genetic susceptibility to gemcitabine-cisplatin regimens for squamous cell and adenocarcinoma and support the use of both lymph node and primary tumor for the expression profiling of NSCLC.
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Introduction
Non-small-cell lung cancer (NSCLC) is the leading cause of death from cancer worldwide. 1 Most patients present with advanced disease at diagnosis, and the standard treatment for unresectable disease consists of platinum-based chemotherapy associated with a third-generation agent, such as gemcitabine. 2 In the last few years, a number of molecular biological studies have been carried out to choose chemotherapeutic agents on the basis of patients' gene expression profile.
Promising determinants such as excision repair cross-complementing-1 (ERCC1) and ribonucleotide-reductase regulatory subunit M1 (RRM1) mRNA and/or protein expression levels for gemcitabine-cisplatin therapy in NSCLC patients are gaining momentum. 3 However, other studies showed controversial results and treatments tailored on the basis of expression profiles are far from being standardized. 4, 5 In our study we investigated whether the tumor histology, the stage of the disease and selected candidate polymorphisms could influence the expression of genes involved in drug activity.
Potential candidates to predict which patients are likely to respond to this treatment are genes encoding enzymes of drug metabolism, drug transport across membranes or target proteins. 6, 7 Gemcitabine is transported into the cells mostly by human equilibrative nucleoside transporter-1 (hENT1). 8 Basal expression levels of hENT1 were significantly correlated with the IC 50 values for gemcitabine in 22 NSCLC cell lines, 9 and cancer patients with higher hENT1 expression had longer survival after gemcitabine chemotherapy. 10, 11 As a prodrug, gemcitabine must be phosphorylated to its active di-and triphosphate metabolites which, respectively, inhibit ribonucleotide reductase (RR) and DNA synthesis. 12 Deoxycytidine kinase (dCK) is the rate-limiting enzyme of this biotransformation, and several studies reported that its deficiency is critically involved in gemcitabine acquired resistance in NSCLC cells. 9, 13 Moreover, a clear correlation between dCK activity and gemcitabine sensitivity has been shown in several tumor xenografts, including NSCLC. 14 The amount of phosphorylated metabolites of gemcitabine may be reduced by cellular 5 0 -nucleotidase (5 0 -NT), while gemcitabine itself is inactivated by deamination through cytidine deaminase (CDA); high expression of these catabolic enzymes has been found in tumor cell lines resistant to nucleoside analogs and gemcitabine. 15 An immunohistochemical study in 43 chemonaive locally advanced or metastatic NSCLC patients showed that 5 0 -NT is an independent prognostic factor in gemcitabine-treated patients and low 5 0 -NT levels correlate with a worse overall survival. 16 Recent studies evaluated also specific single-nucleotide polymorphisms (SNPs) within the CDA gene, 17 and found that the CDA A79C was a predictive marker of response, toxicity, time-to-progression and survival in advanced NSCLC patients treated with gemcitabine and cisplatin. 18, 19 Resistance to gemcitabine was also associated with RR overexpression in several cancer cells. 20, 21 In particular, an increase in the expression of the RRM1 has been associated with gemcitabine resistance in NSCLC cell lines, 22 while clinical studies demonstrated that NSCLC patients with low mRNA expression benefited from gemcitabine-cisplatin chemotherapy. 23, 24 In contrast, high expression of RRM1 protein was significantly associated with longer survival in NSCLC who received only surgical treatment, suggesting the use of RRM1 to select patients to be treated with gemcitabine-based adjuvant chemotherapy. 25 However, further work is required to better elucidate RRM1 transcriptional control. Indeed, the RRM1 promoter allelotypes RR37CC-RR524TT were associated with overall and disease-free survival in resected NSCLC patients, but no correlation was found with tumor RRM1 expression. 26, 27 Similarly, no significant association was detected between RRM1 mRNA expression and the RRM1 G2464A SNP, which is apparently associated with chemosensitivity to gemcitabine in 62 cancer cell lines. 28 This SNP, together with the A2455G polymorphism was associated with clinical outcome after gemcitabine treatment in breast cancer patients, but no analyses on RRM1 expression levels in tissues were conducted in this study. 29 Examples on how pharmacogenetic characteristics might affect drug response are also offered by several studies on platinum compounds, which inhibit cell proliferation by damaging DNA through the formation of intra-and interstrand crosslinks. Drug resistance occurs mostly because of detoxification or efficient repair of damaged DNA by the members of the nucleotide excision repair system, including ERCC1. 30 In vitro studies demonstrated that upregulation of ERCC1 is associated with cisplatin resistance 31 and clinical studies demonstrated that response and survival of patients with advanced NSCLC were improved in the presence of low ERCC1 expression. 32, 33 A low ERCC1 expression was also related to better outcome to adjuvant cisplatin-based chemotherapy in patients with completely resected NSCLC. 34 In contrast, the immunohistochemical staining of ERCC1 was not predictive for tumor response and survival after chemotherapy in NSCLC patients selected from a randomized phase III trial comparing cisplatin-gemcitabine and epirubicin-gemcitabine, 4 and there was no correlation between mRNA expression of ERCC1 and chemosensitivity to cisplatin, carboplatin and gemcitabine in a panel of 20 lung cancer cell lines, including 15 NSCLC cell lines. 5 Many studies have documented the relationship between adenocarcinoma histology and better response to EGFR inhibitors, 35 while the addition of bevacizumab to paclitaxel plus carboplatin has been approved for the treatment of patients with advanced NSCLC in a good performance status, excluding patients with histological evidence of predominantly squamous-cell cancer, to avoid severe toxicity. 36 A recent phase III trial reported a significant survival difference in favour of cisplatin/pemetrexed treatment in NSCLC patients harboring the adenocarcinoma or large-cell carcinoma histological group. 37 However, few data are available on the influence of tumor histology and gene expression of molecular determinants of gemcitabine and cisplatin activity. 38 Similarly, no data are available about differences in gene expression levels of these target genes that have a critical role in tumor sensitivity or resistance to anticancer drugs in primary and metastatic NSCLC tissues.
As the choice of several chemotherapy regimens depends on tumor histology, while the availability and use of primary or metastatic tumor tissues are essential for the gene expression analyses, the characterization of the expression of key genes in tumor specimens with different origin and histology may represent a new avenue for optimal drug use and enhance therapeutic success either by selecting responsive patients or by modulation of drug effects with rationally selected drug combinations.
Furthermore, the analysis of genotype-phenotype correlations can elucidate whether polymorphisms related to clinical outcome after gemcitabine regimens affect gene expression levels in tissues, or might have a functional effect on gemcitabine activity regardless of gene expression differences.
For all these reasons, this study addresses the transcription analysis of hENT1, dCK, 5 0 -NT, CDA, RRM1, RRM2 and ERCC1 in primary and metastatic NSCLC tissues with different histology to elucidate discrete pattern of gene expression that may turn into useful markers of Expression of drug-related genes in NSCLC gemcitabine-cisplatin efficacy. In addition, we studied RRM1-and CDA-specific polymorphic variants to evaluate their correlation with gene expression.
Results

Gene expression variability according to tumor histology
We have evaluated a total of 89 frozen microdissected samples from 69 NSCLC patients at different stages of disease (Table 1) . Among these patients, 45 (60.8%) were affected by adenocarcinoma and 25 (33.8%) by squamouscell carcinoma. The four patients with large-cell carcinoma (5.4%) were not included into our statistical analysis because of the small number of cases. In 14 patients, we have been able to collect samples from both the tumor (primary or metastatic lymph nodes) and the normal tissue, and in five of these patients, tissue sampling was performed from primary tumor, lymph nodes and normal tissue (Tables 2  and 3) .
Gene amplification was successful in the large majority of samples, while only one subject enrolled in the study had no suitable RNA for gene expression analysis (which was performed in 88 out of 89 cases).
To find whether the different histological type could influence gene expression, we evaluated the expression levels of dCK, 5 0 -NT, CDA, RRM1, RRM2, hENT1 and ERCC1, normalized to either b-actin or GAPDH, in adenocarcinomas and squamous-cell carcinomas (Tables 4 and 5 ). Taking into consideration the results obtained with both the normalizer, 5 0 -NT was the only gene differently expressed in the two different histotypes (P ¼ 0.018; Table 5 ). However, to keep at minimum the probability to find a statistically significant difference purely by chance, the usual nominal level (a ¼ 0.05) has been lowered to 0.00238 by Bonferroni adjustment for multiple comparisons. Therefore, after the Bonferroni adjustment, no statistically significant differences in expression levels between adenocarcinoma and squamocellular carcinoma samples were detected.
Gene expression variability according to stage disease By using b-actin as housekeeping gene (Table 4) , the study revealed statistically significant differences in gene expression between normal and tumor tissues for several determinants of gemcitabine activity. In particular, analyzing the pool of tumor tissues (primary tumor and lymph nodes), we observed a higher expression of dCK and hENT1 (P ¼ 0.036 and 0.002, respectively) and a significant lower expression of RRM1 and RRM2 (P ¼ 0.001 and 0.038) compared with normal tissues. However, after Bonferroni adjustment only RRM1 and hENT1 expression levels were significantly different between tumor and normal samples. Interestingly, by using GAPDH as housekeeping, the higher difference between tumor and normal tissues was also observed for RRM1, even if not statistically significative.
Finally, ERCC1 expression analysis demonstrated no significant differences between tumor and metastatic cells as well.
In addition, to investigate whether the stage of the disease have any effect on gene expression, we analyzed the expression level of the genes of interest in a pool of 51 Fisher's exact test P ¼ 0.6440. Expression of drug-related genes in NSCLC primary tumors and 23 lymph nodes. Again, after Bonferroni adjustment, no statistically significant difference in gene expression was observed between primary site and metastatic lymph nodes, at least for the genes involved in cisplatin and gemcitabine metabolism.
Heterogeneity between normal and tumor tissues
The analysis of normal samples revealed a higher gene expression variability with respect to tumor samples for each gene analyzed, with coefficient of variation percent values ranging from 14.5 (RRM2, Table 4 ) to 27.5% (hENT1, Table  4 ) for normal tissues versus 5.4 (5 0 -NT, Table 4 ) to 12.8% (dCK), using b-actin. The same trend was observed considering GAPDH as housekeeping gene (Table 5) .
This high variability of gene expression in normal tissues may reflect the heterogeneity of cells forming a tissue. On the contrary, the low variability of tumor cells could be a consequence of the major homogeneity of microdissected tumor tissues.
Furthermore, we observed a significant correlation ( Figure 1 ) in the expression values for each studied gene with respect to RRM1 in normal tissues (average Spearman's r ¼ 0.885), but not in tumor tissues (average Spearman's r ¼ 0.421). However, the higher correlation value in normal tissues could be just the consequence of the previously mentioned heterogeneity of the tissue.
Gene expression variability according to genotype
To evaluate the correlation between the RRM1 G2464A and A2455G polymorphisms and RRM1 expression, as well as between the CDA A79C SNP and CDA expression, we have extracted DNA from 31 out of the frozen microdissected specimens from which we have previously extracted RNA. Among these, 17 (54.8%) were from patients affected by adenocarcinoma and 14 (45.2%) from patients affected by squamous-cell carcinoma. In 21 patients, we had samples from the tumors, while in 10 cases the tissue sampling was performed from lymph nodes. However, we performed Genotyping was successful in all samples, but in one of the cases, the CDA expression in the corresponding tissue was not detectable. For the RRM1 codon 2464 polymorphism, the frequencies of GG, GA and AA genotypes were 6.4, 19.6 and 74.2%, respectively. The wildtype RRM1 A2455A polymorphism had a frequency of 35.5%, whereas the heterozygous AG and homozygous GG variants had a frequency of 45.2 and 19.3%, respectively. In terms of CDA A79C polymorphism, the wildtype (AA) variant was found in 45.2% of cases, whereas the heterozygous AC and CC variants were observed in 45.2 and 9.6% of cases, respectively. The distributions of these polymorphisms are shown in Table 6 , which also shows their allelic frequencies.
All polymorphisms followed Hardy-Weinberg equilibrium, and genotype frequencies for the CDA A79C SNP were comparable with those reported in a previous study in Caucasians affected by NSCLC, 19 as calculated with the w 2 test (P ¼ 0.836). We investigated whether these different genotypes could influence gene expression (Table 6 ) and found no significant association between both RRM1 polymorphisms and gene expression, using the Wilcoxon two-sided for two-samples for the RRM1 G2464A (that is, AA versus GG) and the Kruskal-Wallis test for the RRM1 A2455G (for the AA, AG and GG groups). On the other hand a significant difference was detected between the mean CDA expression in tissues from patients harboring the CDA A79A genotype and the CDA A79C genotype (P ¼ 0.031).
Effects of hENT1 and RRM1 silencing in NSCLC cells
To investigate whether the gene expression variability observed between normal and tumor tissue might affect the cytotoxic activity of gemcitabine, we used siRNA against hENT1 and RRM1 in the A549 and H1703 cell lines. These cells harbor the same CDA A79A and RRM1 A2464A The cytotoxicity to gemcitabine was higher for cells exposed to gemcitabine transfected with siRNA directed against RRM1 (IC 50 , 15.47±1.12 and 21.50±1.66 nM in A549 and H1703 cells, respectively) than for untransfected cells (21.13 ± 0.91 and 26.53 ± 0.93 in A549 and H1703 cells, respectively) and cells transfected with negative-control siRNA (Figure 1c) . In contrast, the transfection with siRNA directed against hENT1 increased the IC 50 values to 31.00 ± 2.19 and 34.13 ± 1.18 nM in A549 and H1703 cells, respectively. As the negative-control siRNA, which did not affect hENT1 and RRM1 expression, did not alter the cell growth in both cell lines, these results indicate that perturbation of the expression of hENT1 and RRM1 by specific siRNAs significantly modulated the cytotoxicity to gemcitabine.
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Discussion
This study is the first to address the potential differences in the expression pattern of determinants of gemcitabine and cisplatin activity, according to tumor localization and histological subtype in NSCLC. In particular, the aim of this research was the comparison of the expression level of genes involved in gemcitabine and cisplatin activity in NSCLC samples with different histology, as well as in primary versus metastatic lung tumors. Indeed, the main histological subtypes of NSCLC have different embryological origins and arise in different anatomical locations (central versus peripheral airways) and therefore might have differing capacities for drug transport, binding, bioactivation and metabolism, which might affect drug activity.
Using the appropriate statistical analyses for multiple comparison adjustment, we have observed a concordance of mean gene expression between primary tumor and node metastasis with respect to all the studied genes. Similarly, in our specimens no statistically significant difference was observed in the comparison of gene expression levels between adenocarcinoma and squamous-cell carcinoma specimens. Moreover, gene amplification showed different patterns of expression for all studied genes, suggesting a possible stratification of the patients on the basis of tissue expression levels of target genes.
These findings have several relevant consequences. The concordance between primary tumor and lymph node suggests that, at least in the panel of the studied genes, tumor specimens for pharmacogenetic studies can be indifferently obtained from metastatic or primary sites.
In addition, the lack of differences in the mean expression values in adenocarcinoma and squamous-cell carcinoma specimens suggests a similar genetic susceptibility of adenocarcinoma and squamous-cell lung carcinoma to cisplatin and gemcitabine. These data are consistent with the heterogeneous response of patients to this combination regimen, 2 and, as a consequence, highlight the need of tailoring the treatment on the basis of the individual expression characteristics, and not on the histological type.
Our results are in agreement with a recent study showing no differences in the outcome after gemcitabine-cisplatin treatment in patients harboring an adenocarcinoma or a squamous-cell carcinoma histotype. 37 On the contrary, patients with adenocarcinoma had better outcome in the regimen containing pemetrexed in association with cisplatin, possibly because of the lower expression levels of the main target of pemetrexed, thymidylate synthase in adenocarcinoma than in squamous-cell carcinoma. 39, 40 The predictive role for histology for pemetrexed was supported by phase II studies and by a retrospective review of two large, randomized, phase III trial. 38 A recent review of 408 publications reported that 11 single-arm or pooled population studies showed 
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a prognostic association between histology and clinical outcomes. 41 Only seven studies suggested that histological subtype was predictive of outcomes in patients with advanced NSCLC treated with chemotherapy regimens, but the design of these studies and/or type of analyses did not allow to clearly distinguish between a prognostic or predictive association, and genetic analysis of determinants of drug activity were missing.
In this study, the only significant variability of mean gene expression was observed for RRM1 and hENT1 in normal and tumor tissues. These results are in agreement with data obtained in previous studies on differences among neoplastic tissue and normal tissue or among neoplastic tissue and chronic inflammation, suggesting that laser microdissection is crucial to obtain more accurate data and address previously unanswerable questions arising from samples characterized by different cellular populations. 42, 43 Indeed, as new cutting-edge quantitative expression analytical procedures and instruments are developed, more rigorous demands must also be placed on sample preparation Expression of drug-related genes in NSCLC techniques, including laser microdissection. The successive validated quantitative PCR analysis was a reliable, sensitive and specific technique to assess mRNA gene expression, even when sample material was limited, such as in lymph node metastasis. This enabled the measurement of mRNA gene expression in 88 out of 89 microdissected samples, and it is noteworthy that techniques used in this study allowed the accurate analysis of tissue gene expression within 6 h after sample delivery to the laboratory.
To evaluate whether modulation of gene expression similar to the gene expression variability detected in the lung tissues might affect the cytotoxic activity of gemcitabine, we performed specific experiments with siRNA gene silencing against hENT1 and RRM1 in one adenocarcinoma and one squamous-cell carcinoma NSCLC cell line. In these experiments, we obtained expression differences comparable with those detected in the clinical samples, and cytotoxicity assays showed a significant modulation of gemcitabine sensitivity. In both cell lines the RRM1-and hENT1-targeting siRNAs caused a significant increase and decrease of gemcitabine sensitivity, respectively. As the negative-control siRNA, which did not affect hENT1 and RRM1 expression, did not alter the cell growth, these results indicate that the modulation of gemcitabine cytotoxicity was determined by the perturbation of the expression of hENT1 and RRM1 by specific siRNA. These results are in agreement with previous studies showing increased sensitivity to gemcitabine after siRNA against RRM1 in pancreatic and lung cancer cell lines. 44, 45 In contrast, the hENT1-targeting siRNA did not affect gemcitabine sensitivity in pancreatic cancer cells, 44 suggesting different sensitivity in different cell lines.
Genetic variants such as mutations and polymorphisms can also affect gene expression, and we have evaluated the correlation between gene expression levels and specific polymorphisms that have been associated with clinical outcome in patients treated with gemcitabine-cisplatin regimens. 19, 27, 29 No significant associations were detected for both RRM1 G2464A and A2455G polymorphisms and RRM1 gene expression. These results are in agreement with a previous study showing no significant association between mRNA levels of wild-type and polymorphic types in RRM1 G2464A alone (P ¼ 0.301), or a combination of several types of RRM1, including RRM1 A2455G, in 62 human cancer cell lines were used, including six lung cancer cell lines. 28 In the same study, the RRM1 G2464A polymorphism demonstrated an association with gemcitabine sensitivity, 30 while together with the A2455G polymorphism was associated with neutropenia after gemcitabine treatment in breast cancer patients. 29 Therefore, further functional studies evaluating coexpressing genes, as well as prospective clinical trial for its application as a predictive biomarker are needed.
A significant difference was detected between the mean CDA expression levels in tissues from patients harboring the CDA A79A and the CDA A79C genotype (P ¼ 0.031). To our knowledge, this is the first study reporting this correlation in NSCLC tissues, which might have important clinical consequences. Indeed previous studies showed a correlation between mRNA expression of CDA in bone marrow mononuclear cells and hematological toxicity, 46 as well as with clinical outcome in gemcitabine-treated patients, 47 but no data were available from tumor tissues. Our results are also in accordance with ex vivo studies demonstrating that CDA enzymatic activity was significantly lower in subjects harboring the A79A genotype, suggesting that the wildtype variant encodes for a protein with reduced activity. 48 These data might explain the correlation of the A79A genotype with clinical benefit, time-to-progression and overall survival in advanced NSCLC patients treated with cisplatin plus gemcitabine. 19 However, functional genomics analysis showed a moderate decrease in CDA activity in the C79C variant with respect to the wildtype genotype, 49 and no effects of this polymorphism on gemcitabine pharmacokinetics were observed in a study carried out in 256 Japanese patients treated with gemcitabine. 50 These conflicting results suggest that genotype-phenotype correlation of CDA, as well as the role of this SNP in the pharmacokinetics/pharmacodynamics of gemcitabine is still unclear, and should be further evaluated with appropriate retrospective and prospective studies including analysis of genotype, gene expression and activity in tissues, pharmacokinetics and correlation with clinical outcome after gemcitabine therapy.
In conclusion, several findings from this study should be taken into account for the translation of data dealing with gene expression and genotyping to clinical practice, and our results might lead to clinically relevant applications. In particular, as gene expression levels for ERCC1 and for the genes involved in gemcitabine activity are not affected by the origin and the histology of the tumor, future studies should enroll NSCLC patients regardless of different histology, and use laser microdissection and PCR techniques in tumor tissues from both surgical resections or lymph node biopsy to tailor patient's treatment.
Materials and methods
Patient characteristics and treatment
From June 2004 to September 2006, a total of 69 patients affected by NSCLC were enrolled. None of them received any previous chemotherapy treatment. Tissues were collected during mediastinoscopy or lung resection procedures. All patients gave written informed consent, and the study was approved by the Institutional Ethics Committee.
Tissue sampling and processing Frozen tissue sections (5 mm) were thawed, fixed in 75% ethanol, and dehydratated in 100% ethanol and xylene. Neoplastic cells were then dissected using the laser microdissector Leica AS/LMD (Leica, Wetzlar, Germany). Lasercaptured cells were pooled in lysis buffer, and DNA and RNA was extracted with the QIAamp DNA and RNA Mini kit, respectively (Qiagen, San Diego, CA, USA). RNA and DNA were dissolved in DNase/RNase-free water, and measured by absorbance reading at 260/280 nm.
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Quantitative PCR analysis From 50 to 500 ng RNA was reverse transcribed as described previously. 10 The resulting cDNA was amplified with the 7900HT sequence detection system (Applied Biosystems, Foster City, CA, USA). Forward and reverse primers and probes were designed with Primer Express 2.0 (Applied Biosystems) on the basis of dCK (NM_000788), 5 0 -NT (NM_012229) and CDA (NM_001785) gene sequence obtained from the GenBank, whereas primers and probes for RRM1 (NM_001033), RRM2 (NM_001034), hENT1 (NM_004955) and ERCC1 were obtained from Applied Biosystems Assay-on-Demand products (Hs00168784, Hs0035724, Hs00191940 and Hs01012158). Validation experiments were carried out with cDNA obtained from QPCR Human Reference Total RNA (Stratagene, La Jolla, CA, USA) to show that the efficiencies of amplification of the target and the two reference genes GAPDH and b-actin were approximately equal. The results showed comparable mean results and variability in the ratio of each target with the two different housekeeping genes, but the use of b-actin allowed the detection of higher expression values in most samples. Specimens were amplified in triplicate with appropriate nontemplate controls, and the coefficient of variation was o2% for all replicates.
SNPs genotyping
The RRM1 A2464G and A2455G and CDA A79C polymorphisms (rs1042858, rs3177016 and rs2072671, respectively) were studied with Taqman probes-based assays (C__12053301_10, C___2769876_20 and C__25472931_20, respectively) using the ABI PRISM 7900HT instrument equipped with the Sequence Detection System version 2.0 software (Applied Biosystems). The PCR reactions were performed using 20 ng of genomic DNA obtained from tissues, diluted in 11.875 ml DNAse-RNAse-free water, 12.5 ml of TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA, USA), with AmpliTaq Gold (Applied Biosystems, Foster City, CA, USA), and 0.625 ml of the assay mix (forward-and reverse-specific primers and the specific probes), in a total volume of 25 ml. After thermal cycling, the 7900HT instrument determined the allelic content of each sample in the plate by reading the generated fluorescence.
In vitro studies Drugs and chemicals. Gemcitabine was a gift from Eli Lilly, Indianapolis, IN, USA. The drug was dissolved in sterile water and diluted in culture medium before use. RPMI-1640 and Dulbecco's modified Eagle's medium media, fetal bovine serum, penicillin (50 IU ml À1 ) and streptomycin (50 mg ml À1 ) were from Gibco (Gaithersburg, MD, USA). All other chemicals were from Sigma (St Louis, MO, USA).
Cell lines. Cell lines were maintained as monolayer cultures in RPMI or Dulbecco's modified Eagle's medium (containing 2 mM L-glutamine) supplemented with 10% fetal bovine serum, penicillin and streptomycin. The human NSCLC cell line H1703 was cultured in RPMI, whereas A549 cells were cultured in Dulbecco's modified Eagle's medium. H1703 cells originate from a patient affected by a squamous-cell carcinoma, A549 cells were from a patient affected by adenocarcinoma. Cells were grown in 75 cm 2 culture flasks (Costar, Cambridge, MA, USA), at 37 1C in 5% CO 2 and 95% air, and harvested with trypsin-EDTA when they were in exponential growth.
Characterization of cell lines for determinants of drug activity. The NSCLC cells used in this study were characterized for gene expression of determinants involved in gemcitabine and cisplatin activity, as described above. Furthermore, we evaluated genetic variations that may influence gemcitabine metabolism and sensitivity, such as the CDA and RRM1 polymorphisms described above.
Modulation of gemcitabine cytotoxicity by siRNA transfection of RRM1 and hENT1. Cells were plated at 10 5 cells per well in six-well plates (Costar) and, after 24 h, were transfected with small interfering RNA (siRNA) oligonucleotide or negativecontrol siRNA using Oligofectamine (Invitrogen, Inc., Carlsbad, CA, USA) to result in a final RNA concentration of 1, 25 and 50 nmol l À1 in serum-free medium, according to the manufacturer's instructions. At 24 h after transfection, we changed the medium to medium supplemented with 10% heat-inactivated fetal bovine serum, but without penicillin/ streptomycin. After an additional 24 h, total RNA was extracted using the QIAamp RNA Mini kit, and the cells were treated with gemcitabine (0.01-100 nM) for 48 h. At the end of drug treatment, the cell growth inhibitory effect of gemcitabine was studied by direct cell count using the trypan blue. Growth inhibition was expressed as the percentage of gemcitabine-untreated controls (untransfected and negativecontrol siRNA-treated cells), and the 50% inhibitory concentration of cell growth (IC 50 ) was calculated by nonlinear least squares curve fitting (GraphPad PRISM, Intuitive Software for Science, San Diego, CA, USA).
The siRNA oligonucleotides for hENT1 and RRM1 (predesigned siRNA, s117290 and s12357, respectively) were purchased from Applied Biosystems-Ambion (Foster City, CA, USA). The negative-control siRNA (Silencer-NegativeControl#1 siRNA), was also purchased from Applied Biosystems-Ambion.
Statistical methods
Demographic and clinical information was obtained from medical records. Summary statistics (mean, s.e., median and coefficient of variation ) for all gene expression normalized either to GAPDH or b-actin by site and histology, as well as frequency distribution of histology by site of tumor were tabulated. Association between site of tumor and histotype were tested using Fisher's exact test. Comparison between gene expression levels for sites (primary versus lymph node) and histology (normal versus adenosquamous and adeno versus squamous carcinoma), as well as for for genotypes (AA, AC, AG and GG) were carried out using either a twosample, two-sided Wilcoxon test or the unpaired t-test, where appropriate. Adjustments for multiple comparisons were made by Bonferroni test. All gene expression normalized Expression of drug-related genes in NSCLC to b -actin or GAPDH were plotted against the values of RRM1, either for normal and pathological specimens. Spearman's correlations among all genes were also calculated. The differences in the cell viability between the control and the treated samples were evaluated with Student's paired t-test. The level of significance was set at 5% using a two-sided analysis.
